CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse

Relapse following anti-CD19 chimeric antigen receptor (CAR) T cell therapy remains a concern in the treatment of refractory B-cell malignancies. Although the CD19Δexon2 splice variant has been linked to treatment failure, reliable pre-treatment biomarkers for relapse risk are lacking. Here, we analy...

Descrición completa

Detalles Bibliográficos

Principais autores:	Søren Helweg Dam, Giorgia Moranzoni, Magnus Haraldson Høie, Signe Modvig, Karin A. W. Wadt, Bodil Als-Nielsen, Kjeld Schmiegelow, Kristoffer Vitting-Seerup, Mike Bogetofte Barnkob, Lars Rønn Olsen
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2026-02-01
Series:	Frontiers in Molecular Medicine
Assuntos:	CAR T-cell therapy CD19 isoform switching relapse prediction splice variant
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fmmed.2026.1763390/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!